Compare STWD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STWD | PCVX |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 7.0B |
| IPO Year | 2009 | 2020 |
| Metric | STWD | PCVX |
|---|---|---|
| Price | $16.02 | $54.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $20.00 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 3.4M | 991.2K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.64% | N/A |
| EPS Growth | ★ 4.55 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $1,844,289,000.00 | N/A |
| Revenue This Year | $283.44 | N/A |
| Revenue Next Year | $17.66 | N/A |
| P/E Ratio | $124.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.11 | $29.10 |
| 52 Week High | $20.84 | $65.00 |
| Indicator | STWD | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 46.81 |
| Support Level | N/A | $52.04 |
| Resistance Level | $18.54 | $56.04 |
| Average True Range (ATR) | 0.27 | 2.38 |
| MACD | -0.03 | -0.48 |
| Stochastic Oscillator | 7.97 | 25.98 |
Starwood Property Trust Inc is a real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans, commercial mortgage-backed securities, and other real estate investments in the U.S., Australia, and Europe. The company has four reportable business segments: Commercial and Residential Lending, Infrastructure Lending, Property, and Investing and Servicing. The majority of its revenue is generated from the Commercial and Residential Lending segment, which engages mainly in originating, acquiring, financing, and managing commercial first mortgages, non-agency residential mortgages (residential loans), commercial mortgage-backed securities (CMBS), residential mortgage-backed securities (RMBS), and other real estate and related debt investments.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.